DARVON-N DIN 00261432
Health Canada record
| Active ingredient(s) | DEXTROPROPOXYPHENE NAPSYLATE 100 MG |
|---|---|
| Dosage form | Capsule |
| Route | Oral |
| Schedule | NARCOTICS (CDSA I) |
| Class | Human |
| ATC | N02AC04 DEXTROPROPOXYPHENE |
| Original market date | 31-Dec-1973 |
| Current status date | 23-Dec-2010 |
| Source | Health Canada DPD |
Establishment licence of the holder
Paladin Pharma Inc. — licence 100234, currently licensed, last inspection rating C (2023-04-17).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DEXTROPROPOXYPHENE NAPSYLATE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 00261459 | DARVON N COMPOUND PULVULE 405 | ELI LILLY CANADA INC | Capsule | DEXTROPROPOXYPHENE NAPSYLATE 100 MG; ACETYLSALICYLIC ACID 375 MG; CAFFEINE 30 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 10142 | 2009-04-08 | New Drug Submission (NDS) | Manufacturer name change |
| 4804 | 2004-07-15 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
International API supply for DEXTROPROPOXYPHENE NAPSYLATE
0 active FDA Drug Master Files.
Request a quote for DARVON-N